Evidence map›Paper›PMID 34194436›Full record

ArticleFrontiers in immunology2021

Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS.

Indra Sarabia, Camille L Novis, Amanda B Macedo, Hiroshi Takata, Racheal Nell, Juyeon C Kakazu, Robert L Furler, Binita Shakya, Heidi L Schubert, Christopher P Hill and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Indra SarabiaDepartment of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, United States.
Camille L NovisDepartment of Pathology, Division of Microbiology and Immunology, University of Utah School of Medicine, Salt Lake City, UT, United States.
Amanda B MacedoDepartment of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, United States.
Hiroshi TakataVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States.
Racheal NellDepartment of Medicine, Division of Infectious Diseases, University of Utah, Salt Lake City, UT, United States.
Juyeon C KakazuVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States.
Robert L FurlerDepartment of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, United States.
Binita ShakyaDepartment of Biochemistry, University of Utah, Salt Lake City, UT, United States.
Heidi L SchubertDepartment of Biochemistry, University of Utah, Salt Lake City, UT, United States.
Christopher P HillDepartment of Biochemistry, University of Utah, Salt Lake City, UT, United States.
Ana Beatriz DePaula-SilvaDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT, United States.
Adam M SpivakDepartment of Medicine, Division of Infectious Diseases, University of Utah, Salt Lake City, UT, United States.
Lydie TrautmannVaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR, United States.
Vicente PlanellesDepartment of Pathology, Division of Microbiology and Immunology, University of Utah School of Medicine, Salt Lake City, UT, United States.
Alberto BosqueDepartment of Microbiology, Immunology and Tropical Medicine, George Washington University, Washington, DC, United States.
University of Utah · USGeorge Washington University · USOregon Health & Science University · USWeill Cornell Medicine · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
X-ray Cryst. CoreP50GM082545 · NIGMS · UNIVERSITY OF UTAH · PI SUNDQUIST, WESLEY I. · 2007 to 2018
$51.1M
SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Alan Edward Greenberg · 2015 to 2026
$29.6M
Virus TransmissionP50AI150464 · NIAID · UNIVERSITY OF UTAH · PI HOPE, THOMAS · 2019 to 2021
$14.9M
Tyrosine Kinase inhibition: The New Front in HIV Cure EffortsR01AI143567 · NIAID · UNIVERSITY OF UTAH · PI COIRAS, MAYTE, PLANELLES, VICENTE · 2019 to 2023
$2.3M
Developing Pathogen Recognition Receptor Agonists as Latency Reversing AgentsR01AI124722 · NIAID · UNIVERSITY OF UTAH · PI BOSQUE, ALBERTO · 2016 to 2020
$2.1M
Preclinical Development of Ingenol and HDACi Toward HIV EradicationR33AI122377 · NIAID · UNIVERSITY OF UTAH · PI PLANELLES, VICENTE · 2018 to 2020
$1.1M
CRISPR/Cas9 technology toward understanding HIV latency in primary cellsR21AI123035 · NIAID · UNIVERSITY OF UTAH · PI PLANELLES, VICENTE, SCHUBERT, HEIDI L · 2016 to 2017
$416k
Reactivation of latent HIV through TLR signalingR21AI106438 · NIAID · UNIVERSITY OF UTAH · PI BOSQUE, ALBERTO · 2013 to 2014
$410k
Mechanisms Governing Latency in Clinically Relevant HIV-1 StrainsF31AI147814 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI SARABIA, INDRA · 2019 to 2020
$62k
NCI NIH HHS P30 CA042014NIAID NIH HHS F31 AI147814NIAID NIH HHS P30 AI117970NIAID NIH HHS P50 AI150464NIAID NIH HHS R01 AI124722NIAID NIH HHS R01 AI143567NIAID NIH HHS R21 AI106438NIAID NIH HHS R21 AI123035NIAID NIH HHS R33 AI122377NIGMS NIH HHS P50 GM082545
6 · The paper itself

Abstract

The mitochondrial antiviral signaling protein (MAVS) is part of the cell's innate immune mechanism of defense. MAVS mRNA is bicistronic and can give rise to a full length-MAVS and a shorter isoform termed miniMAVS. In response to viral infections, viral RNA can be sensed by the cytosolic RNA sensors retinoic acid-inducible gene I (RIG-I) and/or melanoma differentiation-associated protein 5 (MDA5) and activate NF-κB through interaction with MAVS. MAVS can also sense cellular stress and activate an anti-oxidative stress (AOS) response through the activation of NF-κB. Because NF-κB is a main cellular transcription factor for HIV-1, we wanted to address what role MAVS plays in HIV-1 reactivation from latency in CD4 T cells. Our results indicate that RIG-I agonists required full length-MAVS whereas the AOS response induced by Dynasore through its catechol group can reactivate latent HIV-1 in a MAVS dependent manner through miniMAVS isoform. Furthermore, we uncover that PKC agonists, a class of latency-reversing agents, induce an AOS response in CD4 T cells and require miniMAVS to fully reactivate latent HIV-1. Our results indicate that the AOS response, through miniMAVS, can induce HIV-1 transcription in response to cellular stress and targeting this pathway adds to the repertoire of approaches to reactivate latent HIV-1 in 'shock-and-kill' strategies.

Indexed as

Virus ActivationVirus LatencyBiomarkersCD4-Positive T-LymphocytesHIV-1HIV InfectionsHost-Pathogen InteractionsHumansMitochondrial ProteinsModels, BiologicalNF-kappa BOxidative StressReactive Oxygen SpeciesSignal TransductionBiomarkersMitochondrial ProteinsNF-kappa BReactive Oxygen Speciesanti-oxidative stress responseDynasoreHIV-1latencylatency-reversal agentsMAVSreactive oxygen speciesshock and kill

Identifiers

PMID34194436
PMCPMC8236643
OpenAlexW3167384356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.